Mark Stein

[Mark Stein @drmnstein]

Lots of discussion @ASCO #GU21 about cytoreductive nephrectomy and the renal TME. Proud to share CYTOKIK trial in progress w cabozantinib/nivolumab before and after CN in pts w mcRCC

[Wafik S. El-Deiry, MD, PhD, FACP @weldeiry]

Great to see this article about the drug TIC10/ONC201 discovered in my academic lab in 2007 after we performed a chemical library screen while we were at @Penn.

We’ve learned much about its mechanism of action over the years and it has been the thrill of a lifetime to see it get a first ever approval by the @US_FDA on August 6, 2025 for some of the most aggressive middle of the brain tumors with H3K27M mutation.

The discovery followed an earlier discovery that the tumor suppressor p53 links to our innate immune system through control of TRAIL Death Receptor 5 in 1997, work done while my lab was supported by the Howard Hughes Medical Institute (@hhmi_science).

The story is about basic science to clinical impact through precision oncology but there is still much more to be done to help patients.

https://t.co/7nkSTbblE2

@AACR @AmericanCancer @ASCO @AACI_Cancer @WIN_Consortium @Dr_R_Kurzrock @VivekSubbiah @SewantiLimaye @DrRoyHerbst @RoyJensenMD @DrJoannSweasy @DrPhilKantoff @DrRobWinn @billdahutmd @jrgralow @AACRPres
@AshleySumrallMD @SeanLawler20 @NCIDirector @BrownUniversity @bcarneiro7 @lillian_siu

[Andrew Armstrong @AarmstrongDuke]

Radiographic progression without PSA progression: a major issue with a poor prognosis. Identified in two phase 3 trials in mHSPC and nmCRPC in setting of ADT/ARPI. Routing imaging thus recommended! https://t.co/LqPqcGFWKY @DukeCancer @DukeGUCancer @PCFnews @JCO_ASCO

[Eli Van Allen @VanAllenLab]

Here's our latest, where we explored how to augment LLMs with constantly evolving precision oncology knowledge (h/t @moalmanac), followed by collaboration with medical oncologists to test their queries - congrats Helena Jun, et al!

[Mark Stein @drmnstein]

@Dr_RaviMadan Look forward to reading this !

[Kristine Lacuna, MD @KristineLacuna]

Fantastic event dedicated to education and the impact of prostate cancer on our patients, hosted by @WeillCornell @WCMGUcancer @MSK_DeptOfMed @MSKCancerCenter @columbiacancer @nyphospital, at the NY Academy of Medicine. Sign up today! https://t.co/zYFBIqejZD

[Herbert Irving Comprehensive Cancer Center @columbiacancer]

‼️A #clinicaltrial led by Dr. Mark Stein is showing remarkable results against aggressive prostate cancers. Even at low doses, the immune-stimulating drug pasritamig shrank tumors in many late-stage patients. @ColumbiaMed Read more ➡️ @JNJNews https://t.co/my0a14CxEz

[Michael Hofman @DrMHofman]

A new PET biomarker in men with high-risk metastatic castration-resistant prostate cancer. Total tumor volume prognostic for overall survival and predictive for benefit of Lu-177 PSMA-617.

Great data from @ANZUPtrials ENZA-P led by @drlouiseemmett

https://t.co/EQPiLiauPY~

Another 🇦🇺 @TheLancetOncol #theranostics

[bizarMD @BizarMd]

Excited to share a new paper: https://t.co/087iX9SkJd @CellCellPress: a framework to accelerate variant classification, diagnosis & treatment of immune disorders & genetic disorders more broadly. Led by superstar, juggernaut & future dermatologist @zwalsh96

[Advanced Prostate Cancer Consensus Conference @APCCC_Lugano]

Association of Homologous Recombination Repair Alterations With Outcomes in Patients with Metastatic Hormone-Sensitive Prostate Cancer

https://t.co/W55AfWVYFj

Research has shown that around 30% of advanced #ProstateCancer patients have Homologous Recombination / DNA Damage Repair (HRR) alterations (HRRalt), which have been linked to a poorer outlook in metastatic castrate-resistant prostate cancer.

This study, the largest of its kind, investigated the impact of HRRalt on patients with metastatic hormone-sensitive prostate cancer (mHSPC). Analyzing data from 637 U.S. patients, researchers found that those with HRRalt (28.4% of the group) had a significantly shorter time to castrate-resistance (TTCR) when treated with either an androgen receptor pathway inhibitor or a taxane, compared to patients without HRRalt.

While overall survival also trended less favorably in patients with HRRalt, these findings highlight the potential importance of HRRalt in mHSPC prognosis and could help guide future clinical trials and patient discussions.

@chadihcmd
@RyonGraf
@ziremozay
@ggebraelmd
@nsayeghmd
@maughanonc
@EAntonarakis
@neerajaiims
@umangtalking

@OncoAlert
@Silke_Gillessen @AOmlin
@bavilima @nataliagandur

[Oscar Tahuahua @OscarTahuahua]

Stage II seminoma: what’s best? JCO 2025.
Review compares standard chemo/RT vs novel strategies: RPLND, de-escalated chemo, combo therapy.
👨‍⚕️ Men with IIA/IIB seminoma, LN ≤3 cm
✅ All: >90% cure
🔄 RPLND: relapse 10–30%, avoids chemo/RT in ~70%
1/2 @OncoAlert

[Advanced Prostate Cancer Consensus Conference @APCCC_Lugano]

Pasritamig, a First-in-Class, Bispecific T-Cell Engager Targeting Human Kallikrein 2, in Metastatic Castration-Resistant Prostate Cancer: A Phase I Study

https://t.co/JwWSPVqNvL

This phase I trial of pasritamig, a novel bispecific T-cell–engaging antibody targeting KLK2 in metastatic castration-resistant #prostateCancer , demonstrated a manageable safety profile with mostly low-grade adverse events and minimal cytokine release syndrome.

Showed promising preliminary antitumor activity, including a 42.4% PSA response rate and a median radiographic progression-free survival of 7.85 months, supporting further clinical development.

@drmnstein
@DebbieRobbrecht
@DogerStart
@MikeSchweizerMD
@EmilianoCalvo_
@meavdongen
@DrDariaGaut

Ping @OncoAlert 🚨
@Silke_Gillessen @AOmlin
@nataliagandur @bavilima

[UroToday.com @urotoday]

Phase I trial combines ONC-392 with Lutetium-177 for #ProstateCancer. David Wise, MD, PhD @nyulangone joins @TiansterZhang @UTSWMedCenter discussing this phase I trial of ONC-392 + 177Lu-PSMA, targeting Tregs to overcome resistance after lutetium therapy. Early results: safe, no added toxicity—aiming for deeper, longer-lasting responses. #WatchNow > https://t.co/PHY79ZdFCh

[Toni Choueiri, MD @DrChoueiri]

📢 #ASCO25 | mCRPC Ph. I | KLK2×CD3 bispecific pasritamig: First-in-human (n = 174) shows PSA50 42.4%, median rPFS 6.8 m; G≥3 TRAEs 9.2%, no CRS > G1. by Dr. #CapucineBaldini from @GustaveRoussy et al. Full abstract → [https://t.co/yJgcuHCCxP]
@ASCO @ASCOPost @JCO_ASCO
@neerajaiims @montypal @bergsa83
@GlopesMd @VivekSubbiah @OncoAlert
@tompowles1 @OncBrothers @medicalwatchBC @yekeduz_emre
@CParkMD @Silke_Gillessen @PGrivasMDPhD
@TwoOncDocs @OncBrothers @Larvol @nataliagandur @crisbergerot @DrDanielHeng
@TiansterZhang @HammersMD @sonpavde @drenriquegrande @scserendipity1
@BraunMDPhD @Uromigos @AminNassarMD
@ZiadBakouny @DrRanaMcKay @NazliDizman

[Neeraj Agarwal, MD, FASCO @neerajaiims]

Just in from @ASCO #ASCO25 👉📢 Finally a T-cell engager in #prostatecancer mCRPC with minimal CRS syndrome (only grade 1, all outpatient dosing) and promising efficacy👇 Congrats #drbaldini @drmnstein and team @JCO_ASCO @OncoAlert @urotoday @PCF_Science

[Moshe Ornstein MD @MosheOrnsteinMD]

From Challenges to Cures: Improving Outcomes in Patients With Renal Cell Carcinoma | JCO Oncology Practice https://t.co/JbYseNmONy

[Toni Choueiri, MD @DrChoueiri]

The latest collaboration led by the @kaelin_lab and #WuLab with @BraunMDPhD, #SteveCarr, #DerinKeskin @VanAllenLab @DanaFarber_GU @harvardmed @MIT @df_hcc in @CellCellPress: HIF-2, ERV, T cells, HLA, renal cell carcinoma, et al….

https://t.co/haEZPxCwgO

[Jelani Zarif Lab @Zarif_Lab]

We found out last night that the study section scheduled to review our R01 resubmission was cancelled 24hrs before the review. We spent months conducting experiments, writing and revising this proposal for prostate cancer research that represents 4 years of work. @theNCI @NIH

[David Braun @BraunMDPhD]

Fantastic effort by @lena__wirth and the whole team (@LombardiCancer
@DanaFarberNews @hoosiercancer + many others) to understand some key (and targetable?) determinants of anti-PD-1 response/resistance in RCC @CD_AACR

@YaleCancer @Yale_Urology @yalepathology @YaleMed @YaleIBIO

[Ravi A Madan M.D. @Dr_RaviMadan]

What if #immunotherapy 💉could impact #ProstateCancer as seen w/ #PSA 📉 & #PSMA🩻…but we’ve just been looking 👀 in the wrong place?

Stop by @myesmo poster 🖼️ #1614 Sunday in the #ProstateCancer session #ESMO24